Effect of vitamin D administration in vitamin D-deficient pregnant women on maternal and neonatal serum calcium and vitamin D concentrations: a randomised clinical trial

Sima Hashemipour1, Fatemeh Lalooha2*, Shabnam Zahir Mirdamadi3, Amir Ziaee1 and Talaat Dabaghi Ghaleh2

1Metabolic Diseases Research Center, Qazvin University of Medical Science, Qazvin, Iran
2Department of Obstetrics and Gynecology, Metabolic Diseases Research Center, Qazvin University of Medical Science, Qazvin, Iran
3Kowsar Hospital, Qazvin University of Medical Science, Qazvin, Iran

(Submitted 9 October 2012 – Final revision received 14 March 2013 – Accepted 18 March 2013 – First published online 29 April 2013)

Abstract

There are several studies in which a correlation between maternal vitamin D deficiency and serum mineral disorders in the mother and the newborn has been reported. The present randomised clinical trial was designed to investigate the effect of vitamin D administration on maternal and fetal Ca and vitamin D status. The trial was carried out on 160 pregnant women. Vitamin D-deficient (25-hydroxyvitamin D (25(OH)D), <30 ng/ml) pregnant women were recruited at 26–28 weeks of pregnancy. In the control group, a multivitamin supplement containing 400 IU vitamin D₃/d was given. Patients in the treatment group were treated with 50 000 IU vitamin D₃ weekly for a total duration of 8 weeks. At delivery, maternal and fetal Ca and 25(OH)D levels in both groups were compared. In total, 81% of pregnant women were vitamin D deficient. At the time of delivery, Ca and vitamin D levels were higher in the treatment group compared with the control group (92 (SD 3) v. 85 (SD 4) mg/l, respectively, \( P=0.001 \) for serum Ca; 47·8 (SD 11·1) v. 15·9 (SD 6·6) ng/ml, respectively, \( P<0.001 \) for vitamin D). At the time of delivery, 32·7% of women in the control group had hypocalcaemia, while no hypocalcaemic case was detected in the vitamin D-treated group. Mean neonatal serum 25(OH)D was higher in the treatment group compared with the control group (27·7 (SD 5·2) v. 10·9 (SD 4·4) ng/ml, respectively, \( P<0.001 \)). The neonatal Ca level in the treatment group was significantly higher than that of the control group (99 (SD 3) v. 91 (SD 3) mg/l, respectively, \( P<0.001 \)). The administration of vitamin D to pregnant women with vitamin D deficiency improves both maternal and neonatal Ca levels.

Key words: Vitamin D deficiency: Pregnancy: Hypocalcaemia

Vitamin D is an essential substance for maintaining the natural bone architecture. Vitamin D deficiency can lead to complications including osteomalacia and secondary osteoporosis(1). During pregnancy, considerable amounts of Ca are transferred from the mother to the fetus, and the preparation of such supply of Ca is mainly achieved by the regulation of increased intestinal Ca absorption. Moreover, during pregnancy, the concentration of 1,25-dihydroxyvitamin D increases two to three times above the normal range mainly because of the increase in renal 1-α-hydroxylase activity(2). Theoretically, vitamin D deficiency in mothers could lead to a low production of 1,25-dihydroxyvitamin D due to substrate reduction. Maternal 1,25-dihydroxyvitamin D is transported to the fetus through the placenta, and the cord blood vitamin D level is equal to or at most 25% lower than the maternal concentration(3). There are only a few foods that are good sources of vitamin D, and in countries with no food fortification industries, the generation of vitamin D in the skin is the major source of vitamin D in the body. However, many studies have reported high frequencies of vitamin D deficiency in sunny countries(4–7).

Vitamin D deficiency is highly common in Iran, and based on several reports, up to 80% of women living in Tehran suffer from mild to severe vitamin D deficiency(8). Studies on pregnant women have also shown a high prevalence of vitamin D deficiency, particularly in developing countries including Iran(9–13). Maternal vitamin D deficiency has several disadvantages to fetal outcomes. In cross-sectional studies, a correlation of maternal 25-hydroxyvitamin D (25(OH)D) levels with fetal femur volume(14) and newborn weight(15) has been reported.

Abbreviation: 25(OH)D, 25-hydroxyvitamin D.

* Corresponding author: Dr F. Lalooha, fax +98 281 3526035, email mdrc46@yahoo.com
There are limited clinical trials investigating the effect of vitamin D therapy in the mother on the serum mineral status of both the mother and the newborn. In some studies, an improvement in serum Ca concentrations of the mother as well as a reduced possibility of neonatal hypocalcaemia have been reported\(^{16,17}\). In these studies, different doses of vitamin D were used regardless of the mother's initial vitamin D level. The present randomised clinical trial was conducted to investigate the effect of vitamin D administration in pregnant women with vitamin D deficiency on maternal and fetal 25(OH)D and Ca levels.

**Materials and methods**

This was an open-label, randomised clinical trial carried out in Qazvin (Iran) during December 2011 to March 2012. The primary outcome was to evaluate the effect of treating maternal vitamin D deficiency on newborn vitamin D status. Additional analyses were performed to evaluate the effect on maternal and newborn hypocalcaemia (as secondary outcomes). A total of 160 pregnant women at their twenty-four to twenty-six gestational weeks, who were referred for prenatal care to an obstetric clinic, were investigated. Inclusion criteria included a gestational age of 24–26 weeks, singleton pregnancy and a BMI of 19–26 kg/m\(^2\). Exclusion criteria were gestational diabetes or diabetes before pregnancy, severe pre-eclampsia, chronic hypertension, fetal anomaly, oligohydramnios or polyhydramnios, a history of repeated abortion, rheumatoid arthritis, parathyroid disorders, hepatic or renal diseases, preterm delivery (before week 37), and use of aspirin, anti-convulsive and immunosuppressive drugs. Initially, blood samples were collected from pregnant women for the measurement of serum vitamin D levels, and once the results were obtained, those with vitamin D deficiency entered the study. Vitamin D deficiency was defined as serum 25(OH)D less than 30 ng/ml. Participants were randomly

**Table 1. Baseline demographic and reproductive variables of the treatment and control subjects who completed the study**

<table>
<thead>
<tr>
<th></th>
<th>Control group</th>
<th>Treatment group</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n) (after randomisation)</td>
<td>65</td>
<td>65</td>
</tr>
<tr>
<td>(n) (completed the study)</td>
<td>54</td>
<td>55</td>
</tr>
<tr>
<td>Age (years)</td>
<td>27·62</td>
<td>25·05</td>
</tr>
<tr>
<td></td>
<td>4·63</td>
<td>4·62</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>24·43</td>
<td>24·24</td>
</tr>
<tr>
<td></td>
<td>2·53</td>
<td>2·58</td>
</tr>
<tr>
<td>Sunlight exposure time (min/d)</td>
<td>35·64</td>
<td>36·39</td>
</tr>
<tr>
<td></td>
<td>6·1</td>
<td>5·9</td>
</tr>
<tr>
<td>Women using chador (%)</td>
<td>25·9</td>
<td>21·8</td>
</tr>
<tr>
<td>Gestational age at delivery (weeks)</td>
<td>38·5</td>
<td>38·5</td>
</tr>
<tr>
<td></td>
<td>0·11</td>
<td>0·11</td>
</tr>
<tr>
<td>Vitamin D level (ng/ml)</td>
<td>17·5</td>
<td>15·8</td>
</tr>
<tr>
<td></td>
<td>4·8</td>
<td>5·6</td>
</tr>
<tr>
<td>Median vitamin D level (ng/ml)</td>
<td>18·00</td>
<td>16·70</td>
</tr>
<tr>
<td>Ca level (mg/l)</td>
<td>84</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td>3·9</td>
<td>4·2</td>
</tr>
<tr>
<td>Median Ca level (mg/l)</td>
<td>84</td>
<td>86</td>
</tr>
</tbody>
</table>

---

There are limited clinical trials investigating the effect of vitamin D therapy in the mother on the serum mineral status of both the mother and the newborn. In some studies, an improvement in serum Ca concentrations of the mother as well as a reduced possibility of neonatal hypocalcaemia have been reported\(^{16,17}\). In these studies, different doses of vitamin D were used regardless of the mother's initial vitamin D level. The present randomised clinical trial was conducted to investigate the effect of vitamin D administration in pregnant women with vitamin D deficiency on maternal and fetal 25(OH)D and Ca levels.

**Materials and methods**

This was an open-label, randomised clinical trial carried out in Qazvin (Iran) during December 2011 to March 2012. The primary outcome was to evaluate the effect of treating maternal vitamin D deficiency on newborn vitamin D status. Additional analyses were performed to evaluate the effect on maternal and newborn hypocalcaemia (as secondary outcomes). A total of 160 pregnant women at their twenty-four to twenty-six gestational weeks, who were referred for prenatal care to an obstetric clinic, were investigated. Inclusion criteria included a gestational age of 24–26 weeks, singleton pregnancy and a BMI of 19–26 kg/m\(^2\). Exclusion criteria were gestational diabetes or diabetes before pregnancy, severe pre-eclampsia, chronic hypertension, fetal anomaly, oligohydramnios or polyhydramnios, a history of repeated abortion, rheumatoid arthritis, parathyroid disorders, hepatic or renal diseases, preterm delivery (before week 37), and use of aspirin, anti-convulsive and immunosuppressive drugs. Initially, blood samples were collected from pregnant women for the measurement of serum vitamin D levels, and once the results were obtained, those with vitamin D deficiency entered the study. Vitamin D deficiency was defined as serum 25(OH)D less than 30 ng/ml. Participants were randomly
assigned to two treatment and control groups using a computerised random number generator. Enrolment was performed by obstetrician who was responsible for prenatal care. The present study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the Ethics Committee of Qazvin University of Medical Science. Written informed consent was obtained from all subjects. The control group received a multivitamin containing 400 IU vitamin D₃ plus 200 mg elemental Ca daily until the end of pregnancy. Subjects in the treatment group received a weekly dose of 50 000 IU vitamin D₃ for 8 weeks (from 26 to 28 weeks of pregnancy) as well as the drug regimen given to the control group. Participants visited once every 2 weeks during the second trimester and once per week within the third trimester, and parameters such as weight, blood pressure, uterine fundal height and use of the vitamin D supplement and multivitamin were followed up. Following delivery, blood samples (5 ml) from the mother and the umbilical cord were taken after clamping and sent to the hospital laboratory to be centrifuged and kept frozen until use. The Ca level was determined by calorimetry using a commercial kit (Zist-Shimi). Serum Ca less than 85 mg/l was defined as hypocalcaemia. The intra-assay and inter-assay for Ca measurements were 2·3 and 2·6%, respectively. Serum vitamin D was determined by an ELISA reader (Awareness Technology) and a commercial kit (Euroimmun). The intra-assay and inter-assay for 25(OH)D were 3·3 and 6·7%, respectively. Serum 25(OH)D was determined by a commercial kit (Zist-Shimi). Serum vitamin D and Ca levels were not significantly different between the two groups (Table 1).

### Results

Of the 160 pregnant women (81%), 130 had vitamin D deficiency. During the study, twenty-one pregnant women were excluded: one with gestational diabetes (in control group); one with a premature rupture of the membrane in the treatment group; ten in the control group and nine in the treatment group had difficulty to access due to their delivery in other places (Fig. 1). Complete results were obtained from fifty-four subjects in the control group and fifty-five subjects in the treatment group, and statistical analysis was performed on their baseline and outcome data. Mean gravidity, gestational age at delivery, sun exposure time and serum vitamin D and Ca levels were not significantly different between the two groups (Table 1).

| Table 2. Comparison of maternal and neonatal vitamin D and calcium levels in the two groups following the intervention (Mean values, standard deviations and 95% confidence intervals) |
|----------------|----------------|----------------|----------------|----------------|
|                | Control        | Treatment      | Control        | Treatment      |
|                | Mean           | SD             | 95% CI         | Mean           | SD             | 95% CI         |
| Vitamin D level (ng/ml) | 15·9           | 6·6            | 14·1, 17·8     | 47·8*†         | 11·1           | 44·8, 50·8     |
| 25(OH)D < 10 ng/ml (%)   | 22·2           | 11·1           | 11·1, 32·2     | 0*§            | 10·9           | 4·4            |
| 25(OH)D ≥ 30 ng/ml (%)   | 74·1           | 4·4            | 68·4, 85·7     | 0*§            | 62·4           | 38·4, 87·4     |
| Calcium (mg/l)           | 85             | 3·7            | 80·7, 90·1     | 5·2            | 91·9           | 86·7, 97·3     |
| Hypocalcaemia (Ca < 83 mg/l) | 32·7           | 11·1           | 20·2, 46·2     | 0*§            | 91·9           | 86·7, 97·3     |

Mean values were significantly different compared with the control group: *P < 0·0001, **P < 0·01.

† ANCOVA test.
‡ t test.
§ x² test.
Maternal vitamin D and calcium levels

The mean vitamin D level before the intervention was 17·5 (SD 4·8) ng/ml in the control group and 15·8 (SD 5·6) ng/ml in the treatment group (Table 1). At the time of delivery, the serum vitamin D level was significantly higher in the treatment group compared with the control group, with a mean difference of 31·8 (95 % CI 28·3, 35·3) ng/ml (ANCOVA test, \( P = 0·0001 \); Table 2). In the control group, the mean serum 25(OH)D concentration at the end of the study was even lower than the pre-intervention concentration (\( 21·6 \) ng/ml, paired \( t \) test \( P < 0·05 \)), while mean serum 25(OH)D was 31·97 ng/ml higher than the pretreatment level in the treatment group. (\( P < 0·0001 \), paired \( t \) test).

Moreover, the serum concentration of vitamin D in all the vitamin D-treated pregnant women (100 %) was higher than 30 ng/ml at the time of delivery, while in the control group, only two women (3·7 %) had a vitamin D level >30 ng/ml (\( P < 0·0001 \)). The frequency of serum vitamin D <10 ng/ml in the control group was 22·2 (95 % CI 11·1, 33·2) % at the end of the study (\( P < 0·0001 \); Table 2).

Serum Ca concentration was significantly higher in the treatment group at the time of delivery than in the control group, as shown in Table 2 (\( P = 0·001 \)). Before the intervention, hypocalcaemia was present in 32·7 and 29 % of the subjects in the control and treatment groups, respectively. The frequency of hypocalcaemia (Ca <83 mg/l) was 32·7 (95 % CI 20·4, 45·0) % in the control group, whereas hypocalcaemia was not found in the treatment group (\( P = 0·0001 \); Fig. 2). All of the hypocalcaemic subjects before and after the intervention were asymptomatic. None of the subjects had severe hypocalcaemia (Ca <75 mg/l).

Neonatal vitamin D and calcium levels

As shown in Table 2, the mean vitamin D level in the serum sample, obtained from the umbilical cord, was significantly higher in the treatment group compared with the control group (\( 27·7 \) (SD 5·2) v. \( 10·9 \) (SD 4·4) ng/ml, respectively, \( P = 0·001 \)). All newborns in the control group were vitamin D deficient (25(OH)D <30 ng/ml), while the frequency of vitamin D deficiency in the treatment group was 67·3 (95 % CI 55·0, 79·6) %.

![Fig. 2.](https://www.cambridge.org/core/core2018/10282007871776760/750007114513001244)

![Fig. 3.](https://www.cambridge.org/core/core2018/10282007871776760/750007114513001244)
The frequency of serum 25(OH)D < 10 ng/ml was 50.9% (95% CI 57.7, 64.1%) in the newborns of the control group. None of the newborns in the treatment group had 25(OH)D < 10 ng/ml (P = 0.0001; Table 2).

The Ca level in blood samples taken from the umbilical cord was significantly higher in the treatment group than that found in the control group, as shown in Table 2 (mean difference: 7.8 (95% CI 0.63, 9) mg/l, P = 0.0001) and Fig. 3. There were two cases with mild hypocalcaemia in the control group, however, the frequency of hypocalcaemia incidence between the two groups was statistically insignificant.

There was a direct correlation between the neonatal vitamin D levels of both groups and the maternal vitamin D level (r = 0.7, P = 0.001 for the treatment group; r = 0.49, P = 0.001 for the control group; Table 3). No significant correlation was found between the neonatal Ca level and maternal vitamin D.

Discussion

In the present study, 81% of women at 24–28 weeks of pregnancy were vitamin D deficient. After 8 weeks of treatment with vitamin D, mean maternal and neonatal vitamin D and Ca levels were significantly higher in the treatment group compared with the control group. At the end of the study, a high frequency of vitamin D deficiency (96%) and hypocalcaemia (32%) was detected in the pregnant women of the control group, despite using 400 IU vitamin D3/d. There was a strong and direct correlation between the maternal and umbilical cord 25(OH)D levels at the time of delivery.

Several studies performed in Iran and other countries have also indicated a high prevalence of vitamin D deficiency among pregnant women. However, the results are conflicting for the prevalence of vitamin D deficiency among Iranian pregnant women, ranging from 48% in one study to 86% in another study (12,13). Seasonal difference (sampling in the winter or summer) and geographic variation (distance from the sea level) are considered as important factors affecting the reported prevalence of vitamin D deficiency among Iranian pregnant women.

In studies reported from other Asian countries, vitamin D deficiency has also been found to be common in pregnant women (7–11). Vitamin D deficiency among Asian pregnant women is a function of the overall status of vitamin D in these societies. A high prevalence of vitamin D insufficiency has been recognised as a clinical problem in Asian countries for many years. A lack of food enrichment with vitamin D, genetic factors and cultural and nutritional habits are essential factors associated with vitamin D deficiency in Asian people (18–20).

In the present study, there was a high frequency of hypocalcaemia in the control group, but no hypocalcaemia observed in subjects of the vitamin D-treated group. Generally, hypocalcaemia due to high intravascular volume is considered as the major cause of mild hypocalcaemia in pregnancy (23). In the present study, serum albumin levels were not measured and serum Ca was not corrected for serum albumin. However, an interesting finding was the absence of hypocalcaemic patients in the treatment group, despite a prevalence of 29% in the treatment group before the intervention and a continuous high prevalence of hypocalcaemia in the control group at the end of the study. These results suggest that in the cases of gestational hypocalcaemia, even a mild one, a high possibility of vitamin D deficiency must be considered before attributing the condition to the pregnancy-related dilution of albumin.

The effect of maternal vitamin D deficiency during pregnancy on neonates has been the focus of several studies. In the present study and in the majority of other studies, a strong and direct correlation between the maternal and umbilical cord vitamin D levels has been documented (22–25). A strong correlation between the maternal and fetal vitamin D concentrations is predictable, as 25(OH)D in the mother’s serum has the ability to easily pass through the placenta into the blood circulation of the fetus (26). In the present study, relative and absolute vitamin D deficiency was considerably higher among the neonates of the control group, compared with the control group, and in the treatment group, only one infant was found to have absolute vitamin D deficiency (25(OH)D < 20 ng/ml).

In different studies, complications such as the increased risk of infection (26), neonatal hypocalcaemia (27), softening of the skull bone (craniotabes) (28) and decreased growth indices in vitamin D-deficient infants (29,30) have been reported. In the present study, there was no significant difference in the frequency of neonatal hypocalcaemia in the control and treatment groups; however, hypocalcaemic cases were not frequent and were limited to only two infants in the control group.

In brief, vitamin D deficiency in pregnant women was considerably common during the winter in the present study. According to the recent recommendations (31), supplementation with 400 IU vitamin D3/d does not prevent maternal hypovitaminosis D. Treatment of vitamin D-deficient pregnant women improved maternal vitamin D status, prevented hypocalcaemia of pregnancy and increased fetal vitamin D and Ca levels.

The present study has its own advantages and limitations. The advantages were the randomised clinical design, the season of performing the study (winter) and also the inclusion of vitamin D-deficient pregnant women as a necessary criterion to enter the study. The first limitation of the present study was the lack of using placebo, although it does not seem to have produced major effects on laboratory parameters. The second drawback was due to the failure in determining serum albumin levels and thus calculating corrected Ca concentrations, which could have led to decreased serum total Ca levels associated with the pregnancy-related dilution of albumin. However, a considerable difference in
the frequency of hypocalcaemia in the treatment group following vitamin D therapy compared with pretreatment status and also with the control group demonstrates the importance of treating vitamin D-deficient pregnant women to prevent hypocalcaemia.

Acknowledgements

The present study was supported by a grant from the Department of Research of Qazvin University of Medical Sciences. The authors would like to thank the participants involved in the study and the Department of Research of Qazvin University of Medical Science for endorsing the project. The authors’ contributions are as follows: S. H. and F. L. conceptualised the study; S. Z. M., F. L. and T. D. G. participated in the data collection; A. Z. and S. H. wrote the manuscript. All the authors contributed to the interpreting of the results and the writing of the manuscript, and read and approved the final version. None of the authors has a personal or financial conflict of interest.

References